Volume 168, Issue 2

Search all Breast Cancer Research and Treatment articles

April 2018

30 articles in this issue

Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
Hehui Fang
Doudou Huang
Xiaoxiang Guan
Review 13 December 2017 Pages: 287 - 297
Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis
E. A. Underwood
P. A. Rochon
M. C. Tierney
Review 20 December 2017 Pages: 299 - 310
Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition
E. Santana dos Santos
S. M. Caputo
E. Rouleau
Preclinical study 13 December 2017 Pages: 311 - 325
Enrichment of high-grade tumors in breast cancer gene expression studies
M. van Seijen
A. L. Mooyaart
E. H. Lips
Preclinical study Open access 18 December 2017 Pages: 327 - 335
Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
Y. F. Yu
Y. Wang
H. R. Yao
Clinical trial Open access 29 November 2017 Pages: 337 - 348
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Alexios Matikas
Sara Margolin
Jonas Bergh
Clinical trial Open access 30 November 2017 Pages: 349 - 355
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
B. Pistilli
T. Pluard
C. Saura
Clinical trial 02 December 2017 Pages: 357 - 364
^99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis
Jiwei Wang
Tie Fan
Tao Ouyang
Clinical trial 06 December 2017 Pages: 365 - 370
A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer
Mohammed F. K. Ibrahim
John Hilton
Mark Clemons
Clinical trial 06 December 2017 Pages: 371 - 379
A single institution experience with palbociclib toxicity requiring dose modifications
Jun Gong
May Cho
Joanne Mortimer
Clinical trial Open access 07 December 2017 Pages: 381 - 387
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Jie Xie
Jun Cao
Xi-chun Hu
Clinical trial 11 December 2017 Pages: 389 - 399
CD14+ HLA-DR−/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation
Lisa Speigl
Helen Burow
Christopher Shipp
Clinical trial 11 December 2017 Pages: 401 - 411
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
Erik J. Blok
Judith R. Kroep
On Behalf of the IDEAL Study Group
Clinical trial Open access 12 December 2017 Pages: 413 - 420
Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy
Jonna K. van Vulpen
Martina E. Schmidt
Karen Steindorf
Clinical trial 12 December 2017 Pages: 421 - 431
Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work
Claire Falandry
Ivan Krakowski
Gilles Freyer
Clinical trial 14 December 2017 Pages: 433 - 441
Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study
Zhiyu Xia
Kathy B. Baumgartner
Avonne E. Connor
Epidemiology 30 November 2017 Pages: 443 - 455
Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer
T. Reinert
M. Debiasi
C. H. Barrios
Epidemiology 30 November 2017 Pages: 457 - 465
Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors
Sarah J. O. Nomura
Yi-Ting Hwang
Judy Huei-yu Wang
Epidemiology 11 December 2017 Pages: 467 - 479
Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors
Sarah J. O. Nomura
Yi-Ting Hwang
Judy Huei-yu Wang
Correction 11 January 2018 Pages: 481 - 482
Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy
Wentao Li
Carol Chi-Hei Kwok
Lap Ah Tse
Epidemiology 11 December 2017 Pages: 483 - 493
Worse survival after breast cancer in women with anorexia nervosa
Annet Bens
Fotios C. Papadopoulos
Lene Mellemkjær
Epidemiology 12 December 2017 Pages: 495 - 500
Analysis of breast cancer in young women in the Department of Defense (DOD) database
Alexandra S. Zimmer
Kangmin Zhu
Stanley Lipkowitz
Epidemiology 15 December 2017 Pages: 501 - 511
Predictors of survival for breast cancer patients with a BRCA1 mutation
Steven A. Narod
Tomasz Huzarski
Jan Lubinski
Epidemiology 15 December 2017 Pages: 513 - 521
Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy
Marilyn L. Kwan
Song Yao
Joan C. Lo
Epidemiology 16 December 2017 Pages: 523 - 530
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
Zhe Wang
Jing Kong
Rui Ling
Brief Report 28 November 2017 Pages: 531 - 542
Characterization of a novel germline BRCA1 splice variant, c.5332+4delA
Ciyu Yang
Sowmya Jairam
Liying Zhang
Brief Report 28 November 2017 Pages: 543 - 550
Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy
S. N. Han
F. Amant
On behalf of the International Network on Cancer, Infertility and Pregnancy
Brief Report 12 December 2017 Pages: 551 - 557
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
Pauline du Rusquec
Clément Palpacuer
Jean-Sébastien Frenel
Brief Report 15 December 2017 Pages: 559 - 566
Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort
Catherine Duggan
Richard N. Baumgartner
Anne McTiernan
Brief Report 18 December 2017 Pages: 567 - 576
Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
Alejandra F. Pichilingue-Febres
Miguel A. Arias-Linares
Roger V. Araujo-Castillo
Letter to the Editor 21 December 2017 Pages: 577 - 578

Volume 168, Issue 2

Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer

Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis

Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition

Enrichment of high-grade tumors in breast cancer gene expression studies

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

^99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer

A single institution experience with palbociclib toxicity requiring dose modifications

Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study

CD14+ HLA-DR−/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer

Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy

Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work

Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study

Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer

Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors

Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors

Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy

Worse survival after breast cancer in women with anorexia nervosa

Analysis of breast cancer in young women in the Department of Defense (DOD) database

Predictors of survival for breast cancer patients with a BRCA1 mutation

Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy

PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer

Characterization of a novel germline BRCA1 splice variant, c.5332+4delA

Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer

Genetic variation in TNFα, PPARγ, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort

Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.

Navigation